Current agents for the treatment of patients with heparin-induced thrombocytopenia

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 5, 2002, Pages 405-412

  Warkentin, Theodore E ^a  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ARGATROBAN; DANAPAROID; DEXTRAN; FC RECEPTOR; HEPARIN; HIRULOG; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; THROMBOCYTE FACTOR 4; TIROFIBAN; WARFARIN;

ANTIBODY DETECTION; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG HALF LIFE; GANGRENE; HEART SURGERY; HEMODIALYSIS; HUMAN; PATHOGENESIS; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0036320729     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200209000-00011     Document Type: Review

References (69)

1. Heparin-induced thrombocytopenia/thrombosis
2. Treatment of heparin-induced thrombocytopenia: An overview
3. Heparin-induced thrombocytopenia: Yet another treatment paradox?
4. The paradoxes of heparin-induced thrombocytopenia
5. Legal aspects of heparin-induced thrombocytopenia: U.S. perspectives
6. Legal aspects of heparin-induced thrombocytopenia: European perspectives
7. Delayed-onset heparin-induced thrombocytopenia and thrombosis
8. Delayed-onset heparin-induced thrombocytopenia
9. Nonimmune heparin-platelet interactions: Implications for the pathogenesis of heparin-induced thrombocytopenia
10. Heparin-dependent antigens in heparin-induced thrombocytopenia
11. Molecular immunopathogenesis of heparin-induced thrombocytopenia
12. The platelet Fc receptor in heparin-induced thrombocytopenia
13. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia
14. Frequency of heparin-induced thrombocytopenia
15. Clinical picture of heparin-induced thrombocytopenia
16. Immune vascular injury in heparin-induced thrombocytopenia
17. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia
18. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8
19. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody
20. Temporal aspects of heparin-induced thrombocytopenia
21. Laboratory testing for heparin-induced thrombocytopenia
22. Differential diagnosis of acute thrombocytopenia
23. Pseudo-heparin-induced thrombocytopenia
24. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
25. History of heparin-induced thrombocytopenia
26. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis
27. Trousseau's syndrome treated with long-term subcutaneous lepirudin
28. Warfarin-induced skin necrosis and venous limb gangrene with heparin induced thrombocytopenia
29. Argatroban therapy in heparin-induced thrombocytopenia
30. Argatroban
31. Argatroban: A viewpoint
32. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia
33. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
34. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin
35. Transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia
36. Postpartum coronary artery dissection complicated by heparin induced thrombocytopenia and thrombosis
37. Anticoagulation with a selective thrombin inhibitor in a woman with heparin-induced thrombocytopenia
38. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia
39. Recombinant hirudin in clinical practice: Focus on lepirudin
40. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies
41. The use of lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia during major vascular surgery
42. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports
43. From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia
44. Bivalirudin (Angiomax) for angioplasty
45. Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
46. Danaparoid for the treatment of heparin-induced thrombocytopenia
47. Heparin-induced thrombocytopenia and thrombosis syndrome: In vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin
48. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II
49. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia
50. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: A clinical outcome study
51. Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis
52. Hemodialysis in heparin-induced thrombocytopenia
53. A case review: Anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia
54. Use of recombinant hirudin in heparin-induced thrombocytopenia and thrombosis (HITT) and renal failure-a case report
55. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis
56. Anticoagulation with hirudin for continuous veno-venous hemodialysis in liver transplantation
57. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia
58. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: Successful re-exposure to heparin
59. Successful management strategy for mechanical assistance and heart transplantation in patients suffering from heparin-induced thrombocytopenia type II
60. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban
61. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II
62. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting
63. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass
64. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia
65. The relation between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery
66. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass
67. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations
68. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia